Regeneron

$514.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$5.74 (+1.13%) Today
$0.00 (0.00%) As of 5:00 PM EST after-hours

Why Robinhood?

You can buy or sell Regeneron and other stocks, options, and ETFs commission-free!

About REGN

Regeneron Pharmaceuticals, Inc. Common Stock, also called Regeneron, is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY. The listed name for REGN is Regeneron Pharmaceuticals, Inc. Common Stock.

CEO
Leonard S. Schleifer
Employees
8,100
Headquarters
Tarrytown, New York
Founded
1988
Market Cap
54.85B
Price-Earnings Ratio
18.79
Dividend Yield
Average Volume
964.31K
High Today
$518.92
Low Today
$509.20
Open Price
$513.69
Volume
497.79K
52 Week High
$664.64
52 Week Low
$328.13

Collections

REGN News

CNBCNov 23

CNBC Transcript: Regeneron Chairman and CEO Dr. Leonard Schleifer Speaks with CNBC's Meg Tirrell on "Squawk Box" Today

WHEN: TODAY, MONDAY, NOVEMBER 23 WHERE: CNBC'S "SQUAWK BOX" Following is the unofficial transcript of a CNBC interview with Regeneron Chairman & CEO Dr. Leona
BenzingaNov 23

Looking Into Regeneron Pharmaceuticals's Return On Capital Employed

Looking at Q3, Regeneron Pharmaceuticals (NASDAQ: REGN) earned $1.05 billion, a 60.44% increase from the preceding quarter. Regeneron Pharmaceuticals also poste
CNBCNov 23

Regeneron will provide 300,000 doses of Covid treatment for U.S. by early January, CEO Schleifer says

Regeneron will provide the U.S. with 300,000 doses of its newly authorized Covid-19 antibody treatment by early January, the company's CEO Dr. Leonard Schleifer

REGN Earnings

$0.00
$2.79
$5.57
$8.36
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 4, Pre-Market

You May Also Like

More REGN News

CNBCNov 23

Regeneron CEO Dr. Leonard Schleifer on distribution of Covid-19 antibody cocktail

Regeneron CEO Dr. Leonard Schleifer on distribution of Covid-19 antibody cocktail Regeneron CEO Dr. Leonard Schleifer said Monday morning that they'll have 300
CNBCNov 23

Stocks making the biggest moves in the premarket: Merck, Korn Ferry, Regeneron & more

Take a look at some of the biggest movers in the premarket: Merck (MRK) – Merck is buying privately-held drug maker OncoImmune for $425 million cash. OncoImmun
Financial TimesNov 22

Coronavirus: Ohio has record one-day cases, Pennsylvania tightens restrictions — as it happened

Despite the pandemic, American consumers are forecast to open their wallets this holiday shopping season — even if they will be doing much of it online. Over th
New York TimesNov 22

Covid-19 Live Updates: Antibody Treatment Given to Trump Gets F.D.A. Emergency Approval

Live Updated Nov. 22, 2020, 10:55 a.m. ET Nov. 22, 2020, 10:55 a.m. ET Covid-19 Live Updates: Antibody Treatment Given to Trump Gets F.D.A. Emergency Approval N
MarketWatchNov 22

Regeneron antibody ‘cocktail’ wins emergency-use authorization from FDA

U.S. health officials Saturday agreed to allow emergency use of a second antibody drug to help the immune system fight COVID-19, an experimental medicine that P
BenzingaNov 22

Regeneron's COVID Treatment Gets Emergency FDA Approval

The U.S. Food and Drug Administration has issued emergency use authorization for Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail. Why